BioMarin’s $39 Million Stockholder Settlement Has Final Approval

BioMarin Pharmaceutical Inc. will pay $39 million to settle a securities class action for allegedly misleading investors about the progress of new hemophilia therapy it was developing with a federal judge Wednesday approving the plan.

US District Judge William H. Orrick for the US District Court for the Northern District of California said he would sign the order for the mediated, non-reversionary settlement that provides cash to a class of holders of BioMarin common stock from March 3, 2020, through Aug. 18, 2020.

• “I do think that the settlement is a reasonable settlement for the class and the attorneys’ fees ...